Status:
COMPLETED
Efficacy Study of Selective Tibial Neurotomy in the Treatment of the Spastic Equinovarus Foot Among Adult Hemiplegic Patients
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborating Sponsors:
Fonds National de la Recherche Scientifique
Conditions:
Spastic Equinovarus Foot
Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Spastic equinovarus foot (SEF) is a major cause of disability in stroke patients. Treatments may include physical therapy, orthosis, botulinum toxin (BTX) injections and selective neurotomy. Several ...
Detailed Description
INTRODUCTION Stroke is the third cause of death and the leading cause of handicap among industrialized countries (1). Spasticity following stroke is responsible for spastic equinovarus foot (SEF) in ...
Eligibility Criteria
Inclusion
- Chronic stroke patients (more than 6 months after stroke)
- SEF due to spasticity of the calf muscles
- Positive effects of lidocaïne selective motor nerve block
- No associated tendinosous retraction: ankle dorsiflexion ≥ 0°after block
- Insufficient benefit of adaptated kinesitherapy
- Gait ability allowing an instrumented gait analysis
Exclusion
- Pregnant women
- BTX injection in the lower limb during the 6 months before inclusion
- BTX injection in another limb during the 6 months before inclusion
- patients unable to walk without orthosis on a treadmill
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00825097
Start Date
October 1 2008
End Date
December 1 2011
Last Update
December 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Université Catholique de Louvain - Cliniques universitaires Saint-Luc
Brussels, Belgium, 1200